Exploring Clinical Approaches to Managing CAR-T and Bispecific Therapy Toxicities
Andrew Lin, PharmD, Memorial Sloan Kettering Cancer Center, New York, New York, discussed strategies to mitigate and manage toxicities associated with CAR T-cell and bispecific antibody therapies at the 2025 Lymphoma, Leukemia & Myeloma (LL&M) Congress APP Institute in New York, New York.
He emphasized distinguishing efficacy from toxicity, underscoring that adverse events such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and cytopenias can be proactively managed without compromising treatment outcomes.
The session highlighted practical approaches to toxicity evaluation, supportive care interventions, and strategies to expand access by improving tolerability of these cellular therapies.
Transcript:
Hi, my name's Andrew Lin. I'm the clinical pharmacy manager for bone marrow transplant (BMT) and cellular therapy at Memorial Sloan Kettering. I'm here at the APP Institute giving a talk on how to mitigate and manage CAR-T and bispecific antibody toxicities.
I spoke with Alison Tanner and we really highlighted some of the basics like what is CRS, what is ICANS—but also what are some of the approaches that we can do to help minimize and broaden the availability of these therapies and what can we do to help make them more tolerable as well. We examined some evidence that looked at how toxicity and efficacy are not related together for these therapies. We really need to separate them and make them as tolerable as possible.
We discussed also some of the management of cytopenias and looking at the different etiologies and evaluations that should be done. We then hit the highlights of different treatment options that are available for both managing that and the other side effects that we just discussed.
Source:
Lin A. Early AE Intervention in CAR-T and Bispecific Treatments: CRS, Neurotoxicity & Cytopenia Protocols. Presented at Lymphoma, Leukemia & Myeloma Congress APP Institute; October 18, 2025. New York, NY.
© 2025 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.
The NP/PA Institute is a new offering from the Oncology Learning Network that provides microburst education to oncology advanced practitioners. The platform offers year-round digital non-accredited learning modules through animated short videos, multimedia interviews with key opinion leaders, interactive content to test your knowledge, and more!
